The effects of interventional mitral valve repair using the MitraClip System on the results of pulmonary function testing, pulmonary pressure and diffusing capacity of the lung.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
11 05 2021
Historique:
received: 02 10 2020
accepted: 27 04 2021
entrez: 12 5 2021
pubmed: 13 5 2021
medline: 22 12 2021
Statut: epublish

Résumé

The study analyzes changes in lung function, pulmonary pressure and diffusing capacity of the lung in patients with mitral valve regurgitation (MR) treated by MitraClip implantation. A total of 43 patients (19 women and 24 men with an average age of 78.0 ± 6.6 years) who were able to perform pulmonary function testing including diffusing capacity of the lung for carbon monoxide (DLCO), vital capacity (VC), total lung capacity (TLC), residual volume (RV) and forced expiratory volume in 1 s (FEV1) before and 6 weeks after MitraClip implantation participated in this study. Furthermore, clinical and echocardiographic parameters including systolic pulmonary artery pressure (sPAP), left ventricular ejection fraction (LVEF) and left atrial diameter (LAD) measurements were recorded in all patients. The procedure was performed successfully in all 43 patients leading to a reduction of MR in 97.7% of cases. One patient died on day 4 after the intervention most likely due to pulmonary artery embolism. Six weeks after the implantation 79.1% of patients showed a MR of at most mild to moderate. Furthermore, we could demonstrate a significant reduction of systolic pulmonary artery pressure during follow-up (from 48.8 ± 11.4 mmHg to 42.9 ± 9.0 mmHg (t(41) = - 2.6, p = 0.01). However, no changes in LVEF were detected. Comparing pre and post implant lung function tests, no significant alterations were seen for VC, TLC, DLCO and FEV1. Though, in a subgroup of patients with moderate to severe preexisting deterioration of DLCO at the baseline (max. 50%) the MitraClip procedure resulted in a significant improvement in DLCO (37.8% ± 9.0 to 41.6% ± 10.0, p < 0.001). Treatment of MR with the MitraClip system successfully reduces MR severity in the vast majority of patients. Consecutively, a reduction in pulmonary pressure could be observed, however no changes in LVEF were obvious. Lung function tests remained unaltered during follow-up. However, in a subgroup of patients with severe preexisting deterioration of DLCO the MitraClip procedure resulted in a significant improvement in DLCO. Name of the registry: Die Auswirkung der interventionellen Mitralklappenreparatur mit MitraClip-System auf die Ergebnisse der Lungenfunktionsmessung. DRKS00022435; Date of registration: 09/07/2020 'Retrospectively registered'; URL of trial registry record: https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022435 .

Sections du résumé

BACKGROUND
The study analyzes changes in lung function, pulmonary pressure and diffusing capacity of the lung in patients with mitral valve regurgitation (MR) treated by MitraClip implantation.
METHODS
A total of 43 patients (19 women and 24 men with an average age of 78.0 ± 6.6 years) who were able to perform pulmonary function testing including diffusing capacity of the lung for carbon monoxide (DLCO), vital capacity (VC), total lung capacity (TLC), residual volume (RV) and forced expiratory volume in 1 s (FEV1) before and 6 weeks after MitraClip implantation participated in this study. Furthermore, clinical and echocardiographic parameters including systolic pulmonary artery pressure (sPAP), left ventricular ejection fraction (LVEF) and left atrial diameter (LAD) measurements were recorded in all patients.
RESULTS
The procedure was performed successfully in all 43 patients leading to a reduction of MR in 97.7% of cases. One patient died on day 4 after the intervention most likely due to pulmonary artery embolism. Six weeks after the implantation 79.1% of patients showed a MR of at most mild to moderate. Furthermore, we could demonstrate a significant reduction of systolic pulmonary artery pressure during follow-up (from 48.8 ± 11.4 mmHg to 42.9 ± 9.0 mmHg (t(41) = - 2.6, p = 0.01). However, no changes in LVEF were detected. Comparing pre and post implant lung function tests, no significant alterations were seen for VC, TLC, DLCO and FEV1. Though, in a subgroup of patients with moderate to severe preexisting deterioration of DLCO at the baseline (max. 50%) the MitraClip procedure resulted in a significant improvement in DLCO (37.8% ± 9.0 to 41.6% ± 10.0, p < 0.001).
CONCLUSIONS
Treatment of MR with the MitraClip system successfully reduces MR severity in the vast majority of patients. Consecutively, a reduction in pulmonary pressure could be observed, however no changes in LVEF were obvious. Lung function tests remained unaltered during follow-up. However, in a subgroup of patients with severe preexisting deterioration of DLCO the MitraClip procedure resulted in a significant improvement in DLCO.
TRIAL REGISTRATION
Name of the registry: Die Auswirkung der interventionellen Mitralklappenreparatur mit MitraClip-System auf die Ergebnisse der Lungenfunktionsmessung.
TRIAL REGISTRATION NUMBER
DRKS00022435; Date of registration: 09/07/2020 'Retrospectively registered'; URL of trial registry record: https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022435 .

Identifiants

pubmed: 33975538
doi: 10.1186/s12872-021-02042-1
pii: 10.1186/s12872-021-02042-1
pmc: PMC8112049
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

235

Références

J Am Coll Cardiol. 2015 Mar 31;65(12):1231-1248
pubmed: 25814231
Wien Klin Wochenschr. 2018 Mar;130(5-6):168-171
pubmed: 29209824
Eur Heart J. 2016 Feb 21;37(8):703-12
pubmed: 26614824
Curr Cardiol Rep. 2017 Aug;19(8):73
pubmed: 28688022
Anaesthesia. 2014 Aug;69(8):860-7
pubmed: 24801455
Pulm Circ. 2020 Feb 19;10(1):2045894019891912
pubmed: 32128158
Front Med (Lausanne). 2020 Oct 07;7:570016
pubmed: 33117832
Circ Cardiovasc Interv. 2017 Apr;10(4):
pubmed: 28314742
Respiration. 2004 Jul-Aug;71(4):348-52
pubmed: 15316207
Pulm Circ. 2019 Dec 27;9(4):2045894019894531
pubmed: 31908765
Jpn Circ J. 1971 Nov;35(11):1391-7
pubmed: 5172349
Am Heart J. 2016 Nov;181:26-34
pubmed: 27823690
Am Rev Respir Dis. 1984 Sep;130(3):400-6
pubmed: 6476591

Auteurs

Lucie Kretzler (L)

Clinical Study Center (CSC), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany. Lucie.Kretzler@charite.de.

Stephan Große (S)

Department of Internal Medicine and Cardiology, Pirna Hospital, Pirna, Germany.

Stephan Wiedemann (S)

Department of Internal Medicine and Cardiology, Pirna Hospital, Pirna, Germany.

Carsten Wunderlich (C)

Department of Internal Medicine and Cardiology, Pirna Hospital, Pirna, Germany.

Chris Nowak (C)

Department of Internal Medicine and Cardiology, Pirna Hospital, Pirna, Germany.

Christian Riedel (C)

Department of Internal Medicine and Cardiology, Pirna Hospital, Pirna, Germany.

Tomáš Sieger (T)

Department of Cybernetics, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czech Republic.

Steffen Schoen (S)

Department of Internal Medicine and Cardiology, Pirna Hospital, Pirna, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH